Edwards Lifesciences Corporation (NYSE: EW) announced two-year data from its TRISCEND II trial showing sustained patient benefits from the EVOQUE transcatheter tricuspid valve replacement system. The data was presented at the American College of Cardiology Annual Scientific Session.

The trial demonstrated near elimination of tricuspid regurgitation, improvements in health status and quality of life, no added device-related risk, and lower all-cause mortality when accounting for patient crossover. The results extend findings previously presented at the European Society of Cardiology Congress.

"There is a significant patient population suffering with debilitating symptoms from tricuspid regurgitation with very limited treatment options," said Dr. Vinod Thourani, Bernie Marcus Chairman at Piedmont Heart Institute. "Our analyses, including the many highly symptomatic crossover patients, showed significantly improved outcomes for all of the EVOQUE treated patients."

The 18-month TRISCEND II data showed achievement of hard endpoint benefits for patients with the most severe tricuspid regurgitation who received EVOQUE therapy, along with superior quality of life benefits regardless of baseline tricuspid regurgitation severity.

Edwards corporate vice president Daveen Chopra noted that evidence on EVOQUE includes data on more than 1,000 patients in the STS/ACC TVT Registry, demonstrating consistent near elimination of tricuspid regurgitation and improved quality of life across the tricuspid patient population.

The EVOQUE system has received approval in both the United States and Europe for transcatheter tricuspid valve replacement procedures.